About Lectus Therapeutics
Lectus Therapeutics is a UK biopharmaceutical company with a proprietary functional proteomics screening platform (LEPTICS), enabling the discovery and development of novel, small molecule modulators of ion channels.
Missing: Lectus Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Lectus Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Lectus Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Lectus Therapeutics is included in 2 Expert Collections, including Omics.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Latest Lectus Therapeutics News
Feb 25, 2015
Takeda makes strategic investment in Lectus Therapeutics Through its venture capital arm, Takeda has recently invested in three emerging biotechnology ventures, including Lectus Therapeutics, a functional proteomics-focused company. Datamonitor's Mark Belsey explains how this will strengthen Takeda's long-term pipeline development and help to drive the company's increasingly globalized R&D collaboration infrastructure... Takeda is Japan's largest pharmaceutical firm and was ranked in the top 20 in terms of ethical pharmaceutical sales in 2003. The company had cash reserves of $9.2 billion in 2003 and a reasonably low level of debt. Therefore, there is scope for Takeda to increase licensing and M&A activity to boost pipeline development. The company is currently focusing on expanding its early-stage pipeline, utilizing an increasingly globalized R&D collaboration infrastructure. Historically, Takeda has used its position as an attractive development and marketing partner for smaller Japanese companies to generate a number of Phase I and II products, which would then drive long-term pipeline development. However, Takeda's R&D alliance strategy is becoming increasingly focused towards international partners, to enable it to rapidly develop its pipeline. Takeda is currently building an international alliance network utilizing its joint venture with Abbott, TAP, to support business development, in addition to expanding its venture arm, Takeda Research Investment (TRI), to drive innovation. TRI helps to drive the development of Takeda's international alliance network Headquartered in California, TRI made key investments in three early-stage biotechnology ventures in the US and the UK in May 2004. Of these, the only named biotechnology venture was Lectus Therapeutics, which is based in Bristol, UK. TRI's investment in Lectus focused on the latter's proprietary functional proteomics platform known as LEPTICS, designed to generate highly selective ion channel modulator leads to treat urinary bladder disorders, angina and hypertension. Roland Kozlowski, co-founder and CEO of Lectus told Datamonitor, "This strategic partnership with TRI is a huge endorsement of the company's technology and commercial strategy. With the investment from TRI and the competitive advantages afforded by LEPTICS, a technology which clearly differentiates Lectus from other ion channel businesses, the company is positioned to exploit ion channel drug targets that are otherwise inaccessible to existing technologies. This will enable Lectus to advance its own programs, as well as those of its partners, other pharmaceutical and biotech companies, and boosts the company's anticipated valuation to several million dollars. " Major players are exploring emerging biotech opportunities Takeda's investment is characteristic of a growing interest among major pharmaceutical or biotechnology companies (fully integrated players) to explore small molecule or biologics opportunities in the emerging biotech sector. For example, in 2003 Johnson & Johnson purchased Scios (manufacturer of the therapeutic protein Natrecor) while Amgen signed a long-term small molecule development deal with Biovitrum. This trend has continued into 2004. In January, Amgen made a $25 million equity investment in Infinity to develop small molecule therapeutic agents and in April, Genzyme announced its intention to acquire ILEX (manufacturer of the therapeutic antibody Campath and a number of small molecule oncology pipeline programs) for more than $1 billion. Early-stage funding for biotechs From the point of view of the emerging biotechnology company, the early-stage funding climate has become a difficult place over the past few years, with private equity investments scarce. The growing number of deals involving direct stock purchase, licensing, or M&A established by venture capital arms of leading fully integrated pharmaceutical or biotechnology players has driven greater biotechnology funding. It has also diversified the risk associated with pipeline development for major pharmaceutical or biotechnology companies. The collaborations that TRI has formed this month demonstrate the development of Takeda's venture arm into a valuable contributor to the development of the company's early-stage pipeline. The investments also highlight Takeda's strong long-term development strategies. However, Takeda now needs to address the lack of late-stage pipeline products to ensure continuing success in the short and medium term.
Lectus Therapeutics Frequently Asked Questions (FAQ)
When was Lectus Therapeutics founded?
Lectus Therapeutics was founded in 2002.
Where is Lectus Therapeutics's headquarters?
Lectus Therapeutics's headquarters is located at Cambridge.
What is Lectus Therapeutics's latest funding round?
Lectus Therapeutics's latest funding round is Unattributed.
How much did Lectus Therapeutics raise?
Lectus Therapeutics raised a total of $20.3M.
Who are the investors of Lectus Therapeutics?
Investors of Lectus Therapeutics include Wellcome Trust, Takeda Ventures, Quester Capital Management, Sofinnova Partners, Spark Ventures and 4 more.
Who are Lectus Therapeutics's competitors?
Competitors of Lectus Therapeutics include Cellworks, Icagen, Spinifex, ChanTest, Horizon Therapeutics and 13 more.
Compare Lectus Therapeutics to Competitors
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Altea Therapeutics is using advanced delivery across the skin that aim to improve the efficacy, safety and compliance of drugs and vaccines.
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
Valens Therapeutics is a pharmaceutical company focused on the development of therapeutic products for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer. The company's initial focus is on ophthalmologic disorders caused by unregulated angiogenesis and which offer major opportunities for improved therapies. The ultimate goal is to offer a platform technology of multiple indications for both the ophthalmology and oncology markets. The company's business strategy also includes providing to scientists in the private, government and academic sectors full access to a GMP qualified cleanroom suite for the manufacturing of biologics
Aestus Therapeutics, Inc. is a translational medicine company focused on the treatment of disorders of the nervous system. Aestus's core technology aims to utilize a process for mining both public gene expressions and pharmaceutical data (the Aestus engine).
TheraQuest Biosciences, Inc. is building a diversified portfolio of pharmaceutical products to address pain management.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.